Class Action Lawsuit Filed Against ADMA Biologics Over Alleged Securities Fraud
Berger Montague PC has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors who purchased the company's stock between August 9, 2024 and March 25, 2026. The firm is urging affected investors to seek lead plaintiff status by August 10, 2026. The lawsuit follows a report from financial analyst Culper Research that alleged ADMA inflated its revenue growth in 2025 through channel stuffing—offering rebates and extended payment terms to induce excessive inventory purchases. According to the report, this led to an overstatement of real growth by nearly 23%. Following the release of these allegations on March 24, 2026, ADMA's stock dropped sharply.
Tickers: $ADMA